Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Biotech Jim who wrote (16789)	3/8/1998 11:48:00 AM
From: Henry Niman	Read Replies (3) \| Respond to of 32384

BJ, Although LGND discussed one compound at the meetings, they have talked about entering the clinic this year with compounds discovered under the SBH alliance. I suspect that the progress is much further along than what was presented for general consumption.

To: Biotech Jim who wrote (16789)	3/8/1998 5:20:00 PM
From: Abuckatatime	Respond to of 32384

Biotech Jim, So you don't think that we're likely to see this small molecule or one of its cousins on the pharmacy shelves anytime soon? David Robinson, at the H& Q conf. said as much. Looking back at medsunman's notes I see that DR predicted STATs products on the market by 2005. And apparently Roberston Stephens expected LGND/SKB to select a hematopoietic factor clinical candidate this year. That could mean it has been selected for preclinicals or I suppose could be interpreted to mean that the compound is closer to an IND filing than that. In any case, as you point out, we're years away from eating of the fruit of the JAK-STAT tree. Yet the thrill of discovery is in the air. Henry, thanks for the Univ of PA OncoLink review of GM-CSF and G-CSF. I hadn't visited that site in so long I had forgotten about it. While there visitors might want to read about the investigational hematopoietics as well, IL1,3,6,11 et al. It's a bit dated but it shows the activities of these agents used alone or in combination as well as describing the adverse effects associated with their use. oncolink.upenn.edu